...
首页> 外文期刊>Annals of Surgery >IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody
【24h】

IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody

机译:IDES(Imlifidase):一种新的剂,可切割人IgG并允许穿过高强度供体特异性抗体的成功肾移植

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: The presence of a donor-specific positive crossmatch has been considered to be a contraindication to kidney transplantation because of the risk of hyperacute rejection. Desensitization is the process of removing hazardous preformed donor-specific antibody (DSA) in order to safely proceed with transplant. Traditionally, this involves plasmapheresis and intravenous immune globulin treatments that occur over days to weeks, and has been feasible when there is a living donor and the date of the transplant is known, allowing time for pre-emptive treatments. For sensitized patients without a living donor, transplantation has been historically difficult.
机译:目的:由于超急性排斥的风险,所谓的施主特异性阳性交叉迁移是对肾移植的禁忌症。 脱敏是去除危险的预成型供体特异性抗体(DSA)的过程,以便安全地进行移植。 传统上,这涉及在几天至周内发生的血浆伯术和静脉注射免疫球蛋白治疗,并且当存在活生生剂时是可行的,并且已知移植的日期,允许时间进行预先发布的处理。 对于没有活体供体的敏化患者,移植在历史上困难。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号